Drug
CC-4047
CC-4047 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph phase_1
2
33%
Ph phase_2
3
50%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Other(1)
Detailed Status
Completed5
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed583%
unknown117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
CC-4047 in Treating Patients With Myelofibrosis
NCT00669578
completedphase_2
Pomalidomide for Myelofibrosis Patients
NCT00946270
unknown
Expanded Access for CC-4047
NCT03723096
completedphase_2
CC-4047 (Pomalidomide) for Graft vs. Host Disease
NCT00770757
completedphase_1
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
NCT00482521
Clinical Trials (6)
Showing 6 of 6 trials
NCT00669578Phase 1
CC-4047 in Treating Patients With Myelofibrosis
NCT00946270Phase 2
Pomalidomide for Myelofibrosis Patients
NCT03723096
Expanded Access for CC-4047
NCT00770757Phase 2
CC-4047 (Pomalidomide) for Graft vs. Host Disease
NCT00482521Phase 1
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
NCT00072722Phase 2
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6